How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States
Qualitative findings helped explain state-level variation in methadone treatment following SUD waiver implementation but not for buprenorphine. Strategies identified in higher-performing states may offer useful insights for other states aiming to expand access to methadone for OUD.
Authors
- Deborah J. Cohen (ORCID: https://orcid.org/0000-0003-1689-4574)
- Kyle D. Hart (ORCID: https://orcid.org/0000-0001-8964-204X)
- K. John McConnell (ORCID: https://orcid.org/0000-0003-1280-3196)
- Stephan Lindner (ORCID: https://orcid.org/0000-0002-9577-6287)
- Jordan Byers (ORCID: https://orcid.org/0000-0002-6012-8925)
- Dennis McCarty (ORCID: https://orcid.org/0000-0001-9014-2894)
- Andrea Baron (ORCID: https://orcid.org/0000-0002-6489-0271)
- Brynna Manibusan (ORCID: https://orcid.org/0000-0002-7622-6589)
- Jennifer Hall (ORCID: https://orcid.org/0000-0001-7701-226X)
Institutions
- Oregon Health & Science University (US)
- Public Health Department (IN)
Publication Details
- Journal
- Milbank Quarterly
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1111/1468-0009.70059
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health